Navigation Links
Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
Date:4/7/2008

Alliance for Vaccines and Immunization), and as a senior advisor to BIO Ventures for Global Health on global health policy, an initiative in which he is still engaged. Prior to his consulting roles, he was co-founder, President and Chief Executive Officer of Sequential, Inc., a development-stage oncology company, and Executive Vice President at Inhale Therapeutic Systems, Inc. (now Nektar Therapeutics, Inc.) until July 2002, where he held several key positions, including General Counsel & Secretary, interim Senior Vice President of Operations, Vice President of Intellectual Property and Licensing and Head of Business Development. Mr. Hurst is a graduate of Golden Gate University School of Law and the University of California, Berkeley.

About ITI

The Immune Tolerance Institute (ITI) is a 501(c)(3) non-profit corporation founded in partnership with the University of California, San Francisco (UCSF) to fill critical unmet needs for translating fundamental scientific discoveries into new therapies for the broad range of diseases related to the human immune system, including autoimmune diseases, allergy, asthma, cancer, and cardiovascular and infectious diseases. ITI is a milestone and value-driven company uniquely positioned at the intersection of academia and biopharma that offers a comprehensive constellation of scientific and bio-pharmaceutical industry expertise and services to convert knowledge-based discoveries into market-accessible products for immune system related conditions. At the company's Center for Critical Path Immunology, established as part of a recently announced collaboration with Beckman Coulter, Inc., multiple technology platforms are being deployed in high-throughput fashion to perform comprehensive cellular, molecular and immunological assays on specimens obtained from patients during clinical trials of emerging immunotherapeutics. The mechanistic data that are generated from these assays will be analyzed in parallel with clinical s
'/>"/>

SOURCE The Immune Tolerance Institute Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
2. Seneca Valley High School Student Receives Science Award From MedImmune
3. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
4. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
5. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
6. Immune system protein starves staph bacteria
7. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
8. MedImmune Submits Biologics License Application to FDA for Motavizumab
9. Peptimmune Announces First Close of Series D Private Financing
10. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
11. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... LAUSANNE , Switzerland ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ ... prescription drugs that target unmet medical needs ... that preclinical data on the investigational compounds ... inhibitor) will be presented at the 2015 ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
(Date:4/16/2015)... Washington (PRWEB) April 16, 2015 ... Applied Cancer Science and Resolution Bioscience, Inc. today ... to co-develop a novel, blood-based, clinic ready, Next ... cancer (NSCLC). The collaboration is the first to ... RET, and ROS1 fusions in blinded plasma samples ...
(Date:4/16/2015)... 2015 CCI Global Channel Management, the ... planning management software for major tech and telecom vendors, ... survey of channel vendor programs in software, hardware, and ... How the top IT vendors in each segment ... coming year. , Assessment of the state ...
Breaking Biology Technology:Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... Researchers at Rensselaer Polytechnic Institute and Polyset ... that could lead to dramatic cost savings and ... packaging. , Along with allowing enhanced performance and ... material, called polyset epoxy siloxane (PES), should also ...
... Jan. 28 MedPredict has published,"Thought Leader Insight ... insight for pharma and biotech companies with a,stake ... this disease area., "Given the size of ... for long-term disease control, it is not surprising ...
... Breathing Resistance,Exerciser has successfully accomplished the crossover ... the respiratory therapy market for,COPD patients. Jorge ... the most compact (4") breathing exerciser, originally ... size portable respiratory,exerciser to increase lung capacity ...
Cached Biology Technology:New polymer could improve semiconductor manufacturing, packaging 2New Report Tackles the Changing Landscape for Alzheimer's Diagnostics and Treatments 2It's Good News for The Lungs! 2
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... a specific gene plays a role in the weight-gain response ... animal study suggests that blocking this gene could one day ... disorders, such as diabetes and liver damage, in humans. ... production of this gene, called protein kinase C beta (PKC ...
... University of Liverpool (UoL) have secured a 1.4 million project ... malaria. The project, funded by the Wellcome Trust, aims ... a novel enzyme in the respiratory chain of Plasmodium ... enzyme within the parasite is not found in humans, thereby ...
... Cardiovascular Research Institute, Colchester, Vermont have found that ... inhibitor type-1 (PAI-1) is profibrotic. The results, ... Experimental Biology and Medicine , implicate PAI-1 ... 2 diabetes, as a factor contributing to the ...
Cached Biology News:Researchers uncover 'obesity gene' involved in weight gain response to high-fat diet 2Researchers uncover 'obesity gene' involved in weight gain response to high-fat diet 3LSTM and UoL secure £1.4m ($2m) to develop new 'magic bullet' antimalarial drug 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... formulated for covering tissue sections and cell preparations ... alcohol insoluble end products. UltraMount Plus ... Red or AEC that require an aqueous mounting ... DAB. No heating is required prior to use. ...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... III is intented for ... PBMCs (or lysed whole ... intracellular kinases and appropriate ... Applications: Intracellular Staining (Flow) ...
Biology Products: